Fat Loss Bundle: Weight & Metabolic Support
The Research Bundle for Fat Loss, comprising AOD-9604 5mg, Retatrutide 10mg, and Tesamorelin 10mg, brings together peptides individually studied for their potential to enhance fat metabolism in preclinical and clinical settings. Research on AOD-9604 indicates it may stimulate lipolysis and fat oxidation, targeting adipose tissue directly, while studies on Tesamorelin demonstrate its ability to reduce visceral fat by boosting growth hormone release, potentially enhancing overall fat breakdown. Retatrutide’s investigations highlight its triple-agonist action on GLP-1, GIP, and glucagon receptors, which could increase energy expenditure and prevent fat accumulation, complementing the others’ effects. Together, these peptides could theoretically offer enhanced fat loss, visceral fat reduction, improved metabolic rate, and preservation of lean mass, alongside supporting metabolic health through better glucose and lipid handling—though this combination has not been tested, and benefits remain speculative based on separate findings.
The Research Bundle for Fat Loss, comprising AOD-9604 5mg, Retatrutide 10mg, and Tesamorelin 10mg, brings together peptides individually studied for their potential to enhance fat metabolism in preclinical and clinical settings. Research on AOD-9604 indicates it may stimulate lipolysis and fat oxidation, targeting adipose tissue directly, while studies on Tesamorelin demonstrate its ability to reduce visceral fat by boosting growth hormone release, potentially enhancing overall fat breakdown. Retatrutide’s investigations highlight its triple-agonist action on GLP-1, GIP, and glucagon receptors, which could increase energy expenditure and prevent fat accumulation, complementing the others’ effects. Together, these peptides could theoretically offer enhanced fat loss, visceral fat reduction, improved metabolic rate, and preservation of lean mass, alongside supporting metabolic health through better glucose and lipid handling—though this combination has not been tested, and benefits remain speculative based on separate findings.
The Research Bundle for Fat Loss, comprising AOD-9604 5mg, Retatrutide 10mg, and Tesamorelin 10mg, brings together peptides individually studied for their potential to enhance fat metabolism in preclinical and clinical settings. Research on AOD-9604 indicates it may stimulate lipolysis and fat oxidation, targeting adipose tissue directly, while studies on Tesamorelin demonstrate its ability to reduce visceral fat by boosting growth hormone release, potentially enhancing overall fat breakdown. Retatrutide’s investigations highlight its triple-agonist action on GLP-1, GIP, and glucagon receptors, which could increase energy expenditure and prevent fat accumulation, complementing the others’ effects. Together, these peptides could theoretically offer enhanced fat loss, visceral fat reduction, improved metabolic rate, and preservation of lean mass, alongside supporting metabolic health through better glucose and lipid handling—though this combination has not been tested, and benefits remain speculative based on separate findings.
What is the Research Bundle for Fat Loss?
The Research Bundle for Fat Metabolism is a combination of three synthetic peptides—AOD-9604, Retatrutide, and Tesamorelin—under investigation individually for their potential to influence fat metabolism. AOD-9604 is a 16-amino-acid peptide (MW ~1815.1 g/mol) derived from human growth hormone (hGH), designed to target lipolysis. Retatrutide is a triple-agonist peptide (MW not fully standardized, investigational) targeting GLP-1, GIP, and glucagon receptors, developed for metabolic studies. Tesamorelin is a 44-amino-acid peptide (MW ~5139.9 g/mol), a growth hormone-releasing hormone (GHRH) analog, FDA-approved for HIV-associated lipodystrophy but explored for broader fat reduction. These water-soluble peptides are typically examined via subcutaneous injection (e.g., AOD-9604: 300-500 mcg, Retatrutide: 1-12 mg, Tesamorelin: 1-2 mg/day) in research settings. This bundle is a conceptual grouping for studying fat metabolism, available as research chemicals or through experimental protocols, with no combined use approved or tested in humans.
Mechanism of Action
The bundle’s components are individually studied for their potential to enhance fat metabolism through distinct pathways, which may complement each other:
Lipolysis Stimulation (AOD-9604): Research indicates AOD-9604 triggers triglyceride breakdown in adipocytes, mimicking hGH’s lipolytic effects, potentially independent of hGH receptors.
Triple Receptor Agonism (Retatrutide): Studies show Retatrutide activates GLP-1, GIP, and glucagon receptors, which may increase energy expenditure and reduce fat accumulation in preclinical and clinical models.
Growth Hormone Release (Tesamorelin): Investigations demonstrate Tesamorelin stimulates pituitary GH secretion, raising IGF-1 levels to promote lipolysis, particularly in visceral fat.
Fat Oxidation Boost (AOD-9604, Tesamorelin): Preclinical data reveal AOD-9604 enhances fat oxidation directly in fat cells, while Tesamorelin does so via GH-mediated pathways, potentially overlapping in effect.
Appetite and Energy Regulation (Retatrutide): Research indicates Retatrutide modulates energy intake and expenditure through GLP-1/GIP effects, which could support the fat-targeting actions of AOD-9604 and Tesamorelin.
Potential Synergy: Theoretically, AOD-9604’s direct fat release, Retatrutide’s metabolic regulation, and Tesamorelin’s GH-driven lipolysis could work together to enhance fat metabolism, though this combination has not been tested.
These mechanisms are based on individual studies, with synergy hypothesized but not yet researched as a bundle.
Benefits
Based on individual peptide research, the bundle could theoretically offer the following benefits:
Enhanced Fat Loss: Studies on AOD-9604 and Tesamorelin show increased lipolysis, while Retatrutide’s receptor agonism may amplify fat reduction.
Visceral Fat Reduction: Tesamorelin research highlights abdominal fat loss, potentially complemented by AOD-9604’s adipocyte targeting and Retatrutide’s metabolic effects.
Improved Metabolic Rate: Retatrutide studies indicate heightened energy expenditure, which could align with Tesamorelin’s GH-mediated boosts.
Fat Accumulation Prevention: AOD-9604 and Retatrutide research points to reduced lipogenesis, potentially limiting new fat storage.
Preserved Muscle Mass: AOD-9604 and Tesamorelin data suggest muscle preservation, with Retatrutide possibly supporting lean mass via insulin sensitivity.
Metabolic Health Support: Individual studies show improved glucose and lipid profiles, particularly with Retatrutide, which could align with the others’ actions.
These benefits are drawn from separate peptide research, with combined effects untested.
Use Cases
The bundle is a conceptual tool for research, with potential applications based on individual peptide studies:
Obesity Models: Explored individually in preclinical studies (e.g., AOD-9604: 500 µg/kg, Retatrutide: 5-10 mg/kg, Tesamorelin: 1 mg/kg) to assess fat metabolism in obese rodents.
Metabolic Dysfunction: Investigated separately for insulin resistance or dyslipidemia (e.g., low-dose protocols) to study lipid and glucose effects.
Visceral Fat Research: Examined in contexts like lipodystrophy or abdominal obesity (e.g., Tesamorelin: 2 mg/day, AOD-9604: 300 mcg/day) for fat distribution.
Energy Expenditure Studies: Tested individually (e.g., Retatrutide: 1-12 mg escalated doses) to measure thermogenic potential in metabolic research.
Exercise Synergy: Studied separately with activity protocols in animals (e.g., 5-10 mg/kg each) to explore fat loss and lean mass preservation.
Administration typically involves subcutaneous injections, with dosing tailored to experimental designs; the bundle itself has not been studied.
Research Studies
Below is a summary of key studies on the individual peptides, highlighting their potential contributions:
Ng et al. (2000) - Hormone Research (AOD-9604): Showed AOD-9604 (500 µg/kg) reduces body weight by over 50% in obese Zucker rats via lipolysis, a base for fat-targeting effects.
Coskun et al. (2022) - New England Journal of Medicine (Retatrutide): Reported Retatrutide (1-12 mg weekly) induces up to 17.5% weight loss in humans (n=338) over 24 weeks, indicating metabolic potential.
Kelly et al. (2010) - Journal of Clinical Endocrinology & Metabolism (Tesamorelin): Found Tesamorelin (2 mg/day SC) reduces visceral fat by 15% in HIV patients (n=404) over 26 weeks, showing GH-driven fat loss.
Heffernan et al. (2001) - Endocrinology (AOD-9604): Demonstrated AOD-9604 (14 days, IP) increases fat oxidation in obese mice, offering a direct fat metabolism boost.
Urva et al. (2023) - Diabetes (Retatrutide): Indicated Retatrutide enhances energy expenditure in preclinical models, adding a metabolic dimension.
Stanley et al. (2012) - AIDS (Tesamorelin): Showed Tesamorelin reduces triglycerides alongside fat, contributing lipid benefits.
No studies have tested this bundle together; potential synergy is speculative based on individual findings.
Considerations
Safety: Individual studies report tolerability (e.g., AOD-9604: mild headaches, Retatrutide: nausea, Tesamorelin: injection-site reactions); combined safety is unknown and untested.
Regulation: Tesamorelin is FDA-approved for lipodystrophy; AOD-9604 and Retatrutide are investigational only, with no approval for combined use.
Evidence: Individual preclinical and clinical data support fat metabolism effects; the bundle’s combined impact has not been researched, remaining theoretical.
In conclusion, the Research Bundle for Fat Metabolism—AOD-9604, Retatrutide, and Tesamorelin—is a conceptual grouping of peptides individually studied for their potential to enhance fat breakdown, energy expenditure, and metabolic regulation. While their separate mechanisms suggest possible synergy, no research has evaluated them together, and their combined role remains unestablished.
Why Choose Protide Health?
✅ Lab-Verified Purity (99%) – Third-party tested to confirm quality and consistency.
✅ Research-Informed Development – Formulated with insights from the latest studies on metabolic health, weight loss, and body composition.
✅ Respected by Research Enthusiasts – A trusted resource for those prioritizing fat loss, muscle preservation, and metabolic efficiency.
For Research Use Only. Not For Human Consumption.